BRPI0914802A2 - Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo. - Google Patents

Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo.

Info

Publication number: BRPI0914802A2
Authority: BR; Brazil
Prior art keywords: prodrug; compound; drug
Prior art date: 2008-06-19

Application number

BRPI0914802-7A

Other languages

English (en)

Inventor

Takanobu Kuroita

Yasuhiro Imaeda

Kouichi Iwanaga

Naohiro Taya

Hidekazu Tokuhara

Yoshiyuki Fukase

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-19

Filing date

2009-06-17

Publication date

2015-08-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41282529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0914802(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-17 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2015-08-11 Publication of BRPI0914802A2 publication Critical patent/BRPI0914802A2/pt

2020-10-27 Publication of BRPI0914802B1 publication Critical patent/BRPI0914802B1/pt

2021-05-25 Publication of BRPI0914802B8 publication Critical patent/BRPI0914802B8/pt

Links

150000001875 compounds Chemical class 0.000 title 2
229940002612 prodrug Drugs 0.000 title 2
239000000651 prodrug Substances 0.000 title 2
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Hydrogenated Pyridines (AREA)

BRPI0914802A 2008-06-19 2009-06-17 composto heterocíclico, e, medicamento BRPI0914802B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP2008161049		2008-06-19
JP2008-161049		2008-06-19
JP2009004882		2009-01-13
JP2009-004882		2009-01-13
PCT/JP2009/061438 WO2009154300A2 (en)	2008-06-19	2009-06-17	Heterocyclic compound and use thereof

Publications (3)

Publication Number	Publication Date
BRPI0914802A2 true BRPI0914802A2 (pt)	2015-08-11
BRPI0914802B1 BRPI0914802B1 (pt)	2020-10-27
BRPI0914802B8 BRPI0914802B8 (pt)	2021-05-25

Family

ID=41282529

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0914802A BRPI0914802B8 (pt)	2008-06-19	2009-06-17	composto heterocíclico, e, medicamento

Country Status (38)

Country	Link
US (5)	US8664380B2 (pt)
EP (1)	EP2297114B1 (pt)
JP (3)	JP4800445B2 (pt)
KR (2)	KR101578264B1 (pt)
CN (2)	CN102123990B (pt)
AR (1)	AR072166A1 (pt)
AU (1)	AU2009261153B2 (pt)
BR (1)	BRPI0914802B8 (pt)
CA (1)	CA2728476C (pt)
CL (1)	CL2010001361A1 (pt)
CO (1)	CO6300862A2 (pt)
CR (2)	CR20110001A (pt)
CY (1)	CY1120995T1 (pt)
DK (1)	DK2297114T3 (pt)
DO (2)	DOP2010000381A (pt)
EA (2)	EA019755B1 (pt)
EC (1)	ECSP11010770A (pt)
ES (1)	ES2676289T3 (pt)
GE (2)	GEP20166443B (pt)
HR (1)	HRP20181370T1 (pt)
HU (1)	HUE039416T2 (pt)
IL (1)	IL209282A (pt)
JO (1)	JO3465B1 (pt)
LT (1)	LT2297114T (pt)
MA (1)	MA32483B1 (pt)
MX (2)	MX2010013602A (pt)
MY (1)	MY160771A (pt)
NZ (2)	NZ600238A (pt)
PE (2)	PE20110067A1 (pt)
PL (1)	PL2297114T3 (pt)
PT (1)	PT2297114T (pt)
RS (1)	RS57591B1 (pt)
SG (1)	SG188117A1 (pt)
SI (1)	SI2297114T1 (pt)
TW (2)	TWI472523B (pt)
UY (1)	UY31907A (pt)
WO (1)	WO2009154300A2 (pt)
ZA (1)	ZA201009073B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009051112A1 (ja)	2007-10-15	2009-04-23	Takeda Pharmaceutical Company Limited	アミド化合物およびその用途
EP2243779A4 (en)	2007-12-19	2011-04-20	Dainippon Sumitomo Pharma Co	HETEROCYCLIC BICYCLIC DERIVATIVE
EA019755B1 (ru) *	2008-06-19	2014-06-30	Такеда Фармасьютикал Компани Лимитед	Гетероциклическое соединение и его применение
US9090601B2 (en)	2009-01-30	2015-07-28	Millennium Pharmaceuticals, Inc.	Thiazole derivatives
CA2765527A1 (en)	2009-06-24	2010-12-29	Satoshi Suetsugu	N-substituted-cyclic amino derivative
WO2011079105A1 (en) *	2009-12-23	2011-06-30	Abbott Laboratories	Novel thienopyrrole compounds
PH12012502468A1 (en) *	2010-06-16	2015-05-08	Takeda Pharmaceuticals Co	Crystal of amide compound
US8742097B2 (en)	2010-11-09	2014-06-03	Hoffmann-La Roche Inc.	Triazole compounds I
BR112013011265A2 (pt) *	2010-11-09	2016-11-01	Hoffmann La Roche	derivados de triazol como ligantes para receptores gaba
US20120178813A1 (en)	2011-01-12	2012-07-12	Thetis Pharmaceuticals Llc	Lipid-lowering antidiabetic agent
US9382192B2 (en) *	2012-02-14	2016-07-05	Dow Global Technologies Llc	Nonionic surfactant compositions
WO2013122260A1 (en)	2012-02-15	2013-08-22	Takeda Pharmaceutical Company Limited	Tablet
AU2013283488A1 (en) *	2012-06-26	2015-01-15	Saniona Aps	A phenyl triazole derivative and its use for modulating the GABAA receptor complex
US8765811B2 (en)	2012-07-10	2014-07-01	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
US9382187B2 (en)	2012-07-10	2016-07-05	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
CA2944779A1 (en) *	2014-04-10	2015-10-15	Takeda Pharmaceutical Company Limited	Method for producing heterocyclic compound
WO2015171516A1 (en)	2014-05-05	2015-11-12	Thetis Pharmaceuticals Llc	Compositions and methods relating to ionic salts of peptides
US9242008B2 (en)	2014-06-18	2016-01-26	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of fatty acids
CN107074884A (zh)	2014-06-18	2017-08-18	西蒂斯制药有限责任公司	活性剂的矿物质氨基酸复合物
US10758525B2 (en)	2015-01-22	2020-09-01	MyoKardia, Inc.	4-methylsulfonyl-substituted piperidine urea compounds
JP6906047B2 (ja)	2016-06-03	2021-07-21	テティス・ファーマシューティカルズ・エルエルシー	特異的炎症収束性メディエーターの塩に関連する組成物及び方法
CN108727249A (zh) *	2018-07-07	2018-11-02	台州学院	3-二氟甲基哌啶盐酸盐及其衍生物的合成方法
EP3999504A1 (en)	2019-07-16	2022-05-25	MyoKardia, Inc.	Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL102183A (en)	1991-06-27	1999-11-30	Takeda Chemical Industries Ltd	Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
RU2168510C2 (ru)	1991-07-31	2001-06-10	Такеда Кемикал Индастриз, Лтд.	Гетероциклическое соединение, фармацевтическая композиция, способ антагонизирования ангиотензина ii
IL117659A (en)	1995-04-13	2000-12-06	Dainippon Pharmaceutical Co	Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
EP0832066B1 (en)	1995-06-06	2001-09-12	Pfizer Inc.	Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
UA58494C2 (uk)	1995-06-07	2003-08-15	Зенека Лімітед	Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
BR9606619A (pt)	1995-09-01	1997-12-23	Lilly Co Eli	Antagonistas do receptor de neuropeptídeo y indolil
TWI227240B (en)	2000-06-06	2005-02-01	Pfizer	2-aminocarbonyl-9H-purine derivatives
US7199147B2 (en)	2001-06-12	2007-04-03	Dainippon Sumitomo Pharma Co., Ltd.	Rho kinase inhibitors
US20030078278A1 (en)	2001-06-26	2003-04-24	Pfizer Inc.	Spiropiperidine compounds as ligands for ORL-1 receptor
DE60235114D1 (de)	2001-11-01	2010-03-04	Icagen Inc	Pyrazolamide zur anwendung in der behandlung von schmerz
RU2374236C2 (ru)	2001-12-21	2009-11-27	Ново Нордиск А/С	Амидные производные в качестве активаторов gk
WO2003079973A2 (en)	2002-03-08	2003-10-02	Merck & Co., Inc.	Mitotic kinesin inhibitors
AU2003287057B2 (en)	2002-10-18	2008-08-21	Merck Sharp & Dohme Corp.	Mitotic kinesin inhibitors
US20040204455A1 (en)	2003-04-10	2004-10-14	Cody Wayne Livingston	Piperidine derivative rennin inhibitors
AU2004247615B2 (en) *	2003-06-18	2008-02-21	Astrazeneca Ab	2-substituted 5,6-diaryl-pyrazine derivatives as CB1 modulators
DE602004019229D1 (de)	2003-08-15	2009-03-12	Merck & Co Inc	Inhibitoren von mitotischem kinesin
WO2005018547A2 (en)	2003-08-15	2005-03-03	Merck & Co., Inc.	Mitotic kinesin inhibitors
TW200900399A (en)	2003-10-01	2009-01-01	Speedel Experimenta Ag	Organic compounds
WO2005047251A1 (en)	2003-11-12	2005-05-26	Lg Life Sciences Ltd.	Melanocortin receptor agonists
AR053406A1 (es)	2004-07-09	2007-05-09	Speedel Experimenta Ag	Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
CN101080226A (zh)	2004-08-10	2007-11-28	因塞特公司	酰氨基化合物及它们作为药物的用途
MX2007003858A (es)	2004-10-07	2007-12-11	Vitae Pharmaceuticals Inc	Diaminoalcanos inhibidores de proteasa asparticas.
MX2007005765A (es) *	2004-11-23	2007-07-19	Wyeth Corp	Antagonistas del receptor de la hormona que libera gonadotropina.
GB0428526D0 (en)	2004-12-30	2005-02-09	Novartis Ag	Organic compounds
JP2008533144A (ja)	2005-03-16	2008-08-21	メルクエンドカムパニーインコーポレーテッド	有糸分裂キネシン阻害剤
GB0511063D0 (en)	2005-05-31	2005-07-06	Novartis Ag	Organic compounds
GB0514203D0 (en) *	2005-07-11	2005-08-17	Novartis Ag	Organic compounds
AU2006285915B2 (en)	2005-08-30	2011-02-24	Asahi Kasei Pharma Corporation	Sulfonamide compound
FI20055498A0 (fi)	2005-09-16	2005-09-16	Biotie Therapies Corp	Sulfonamidijohdannaisia
US7618982B2 (en)	2005-12-19	2009-11-17	Nerviano Medical Sciences S.R.L.	Heteroarylpyrrolopyridinones active as kinase inhibitors
EP1968940B1 (en) *	2005-12-30	2014-04-02	Novartis AG	3 , 5-substitued piperidine compounds as renin inhibitors
TW200804359A (en)	2006-01-19	2008-01-16	Speedel Experimenta Ag	Substituted 4-phenylpiperidines
CA2638787A1 (en)	2006-02-16	2007-08-23	Takeda Pharmaceutical Company Limited	Cyclic amine compound and use thereof for the prophylaxis or treatment of hypertension
US7790884B2 (en) *	2006-03-24	2010-09-07	Astellas Pharma Inc.	Acylaminopiperidine compound
GB0607954D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
WO2008009954A1 (en)	2006-07-21	2008-01-24	Astex Therapeutics Limited	Medical use of cyclin dependent kinases inhibitors
WO2008016666A2 (en) *	2006-08-02	2008-02-07	Cytokinetics, Incorporated	Certain chemical entities, compositions, and methods
US20100056497A1 (en) *	2007-01-31	2010-03-04	Dainippon Sumitomo Pharma Co., Ltd	Amide derivative
JP4837701B2 (ja)	2007-04-20	2011-12-14	田辺三菱製薬株式会社	医薬組成物
JP2010163361A (ja)	2007-04-27	2010-07-29	Dainippon Sumitomo Pharma Co Ltd	キノリン誘導体
WO2008139941A1 (en)	2007-04-27	2008-11-20	Takeda Pharmaceutical Company Limited	Substituted imidazole compound and use thereof
JP2010189275A (ja)	2007-06-14	2010-09-02	Dainippon Sumitomo Pharma Co Ltd	ナフタレン誘導体
TWI452044B (zh)	2007-06-15	2014-09-11	Mitsubishi Tanabe Pharma Corp	嗎啉衍生物
WO2009001915A1 (ja)	2007-06-28	2008-12-31	Takeda Pharmaceutical Company Limited	置換イミダゾール化合物およびその用途
JP2010208947A (ja)	2007-06-29	2010-09-24	Dainippon Sumitomo Pharma Co Ltd	キノロン誘導体
JP2010229034A (ja) *	2007-07-26	2010-10-14	Dainippon Sumitomo Pharma Co Ltd	二環性ピロール誘導体
WO2009051112A1 (ja)	2007-10-15	2009-04-23	Takeda Pharmaceutical Company Limited	アミド化合物およびその用途
JP2011037712A (ja)	2007-12-08	2011-02-24	Dainippon Sumitomo Pharma Co Ltd	４−アリールフェニル誘導体
EP2243779A4 (en)	2007-12-19	2011-04-20	Dainippon Sumitomo Pharma Co	HETEROCYCLIC BICYCLIC DERIVATIVE
AR070454A1 (es)	2008-02-27	2010-04-07	Nycomed Gmbh	Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden
US20110098288A1 (en)	2008-03-11	2011-04-28	Jeremy Major	Sulfonamides as zap-70 inhibitors
JP2009298713A (ja) *	2008-06-11	2009-12-24	Daiichi Sankyo Co Ltd	イミダゾチアゾール誘導体
EA019755B1 (ru) *	2008-06-19	2014-06-30	Такеда Фармасьютикал Компани Лимитед	Гетероциклическое соединение и его применение
WO2010126002A1 (ja)	2009-04-28	2010-11-04	塩野義製薬株式会社	ヘテロ環スルホンアミド化合物を含有する医薬

2009
- 2009-06-17 EA EA201170051A patent/EA019755B1/ru not_active IP Right Cessation
- 2009-06-17 CN CN200980132372.7A patent/CN102123990B/zh active Active
- 2009-06-17 PT PT97667489T patent/PT2297114T/pt unknown
- 2009-06-17 BR BRPI0914802A patent/BRPI0914802B8/pt not_active IP Right Cessation
- 2009-06-17 CA CA2728476A patent/CA2728476C/en active Active
- 2009-06-17 AU AU2009261153A patent/AU2009261153B2/en not_active Ceased
- 2009-06-17 ES ES09766748.9T patent/ES2676289T3/es active Active
- 2009-06-17 US US12/457,646 patent/US8664380B2/en active Active
- 2009-06-17 KR KR1020127014751A patent/KR101578264B1/ko not_active Expired - Fee Related
- 2009-06-17 JP JP2010549957A patent/JP4800445B2/ja not_active Expired - Fee Related
- 2009-06-17 HR HRP20181370TT patent/HRP20181370T1/hr unknown
- 2009-06-17 GE GEAP200913059A patent/GEP20166443B/en unknown
- 2009-06-17 NZ NZ600238A patent/NZ600238A/en not_active IP Right Cessation
- 2009-06-17 UY UY0001031907A patent/UY31907A/es not_active Application Discontinuation
- 2009-06-17 TW TW101121074A patent/TWI472523B/zh not_active IP Right Cessation
- 2009-06-17 SG SG2013008842A patent/SG188117A1/en unknown
- 2009-06-17 NZ NZ589825A patent/NZ589825A/xx not_active IP Right Cessation
- 2009-06-17 EP EP09766748.9A patent/EP2297114B1/en active Active
- 2009-06-17 SI SI200931871T patent/SI2297114T1/sl unknown
- 2009-06-17 LT LTEP09766748.9T patent/LT2297114T/lt unknown
- 2009-06-17 US US12/999,428 patent/US8466282B2/en not_active Expired - Fee Related
- 2009-06-17 MY MYPI2010005939A patent/MY160771A/en unknown
- 2009-06-17 EA EA201301040A patent/EA201301040A1/ru unknown
- 2009-06-17 GE GEAP200912066A patent/GEP20135957B/en unknown
- 2009-06-17 CN CN201310292451.2A patent/CN103373985B/zh not_active Expired - Fee Related
- 2009-06-17 HU HUE09766748A patent/HUE039416T2/hu unknown
- 2009-06-17 PE PE2010001164A patent/PE20110067A1/es active IP Right Grant
- 2009-06-17 KR KR1020117001002A patent/KR101207830B1/ko active Active
- 2009-06-17 AR ARP090102193A patent/AR072166A1/es active IP Right Grant
- 2009-06-17 PL PL09766748T patent/PL2297114T3/pl unknown
- 2009-06-17 MX MX2010013602A patent/MX2010013602A/es active IP Right Grant
- 2009-06-17 RS RS20180895A patent/RS57591B1/sr unknown
- 2009-06-17 TW TW098120213A patent/TWI378096B/zh active
- 2009-06-17 PE PE2013001363A patent/PE20140858A1/es not_active Application Discontinuation
- 2009-06-17 WO PCT/JP2009/061438 patent/WO2009154300A2/en not_active Ceased
- 2009-06-17 JO JOP/2009/0216A patent/JO3465B1/ar active
- 2009-06-17 DK DK09766748.9T patent/DK2297114T3/en active
2010
- 2010-11-11 IL IL209282A patent/IL209282A/en active IP Right Grant
- 2010-12-06 CL CL2010001361A patent/CL2010001361A1/es unknown
- 2010-12-08 DO DO2010000381A patent/DOP2010000381A/es unknown
- 2010-12-09 MX MX2012014481A patent/MX338557B/es unknown
- 2010-12-17 ZA ZA2010/09073A patent/ZA201009073B/en unknown
2011
- 2011-01-10 CR CR20110001A patent/CR20110001A/es unknown
- 2011-01-14 MA MA33527A patent/MA32483B1/fr unknown
- 2011-01-19 CO CO11005108A patent/CO6300862A2/es active IP Right Grant
- 2011-01-19 EC EC2011010770A patent/ECSP11010770A/es unknown
- 2011-04-08 JP JP2011086570A patent/JP5592831B2/ja not_active Expired - Fee Related
2012
- 2012-04-13 US US13/446,408 patent/US9045436B2/en active Active
2013
- 2013-05-31 DO DO2013000123A patent/DOP2013000123A/es unknown
- 2013-07-24 CR CR20130360A patent/CR20130360A/es unknown
- 2013-12-27 JP JP2013273076A patent/JP5918746B2/ja not_active Expired - Fee Related
2015
- 2015-03-23 US US14/665,237 patent/US9221836B2/en not_active Expired - Fee Related
- 2015-10-28 US US14/925,259 patent/US20160046601A1/en not_active Abandoned
2018
- 2018-09-04 CY CY181100913T patent/CY1120995T1/el unknown

Also Published As

Publication number	Publication date
CN103373985A (zh)	2013-10-30
PE20110067A1 (es)	2011-02-18
LT2297114T (lt)	2018-08-10
JP2014094950A (ja)	2014-05-22
JP5918746B2 (ja)	2016-05-18
KR101207830B1 (ko)	2012-12-04
US20150191486A1 (en)	2015-07-09
MX338557B (es)	2016-04-21
EP2297114A2 (en)	2011-03-23
EA201170051A1 (ru)	2011-08-30
BRPI0914802B8 (pt)	2021-05-25
NZ589825A (en)	2012-11-30
US20100137587A1 (en)	2010-06-03
DK2297114T3 (en)	2018-07-09
KR20120084778A (ko)	2012-07-30
PT2297114T (pt)	2018-07-26
EA201301040A1 (ru)	2014-01-30
MY160771A (en)	2017-03-15
MX2010013602A (es)	2011-03-15
CR20110001A (es)	2013-03-15
KR101578264B1 (ko)	2015-12-16
HUE039416T2 (hu)	2018-12-28
AU2009261153A1 (en)	2009-12-23
TWI472523B (zh)	2015-02-11
US8664380B2 (en)	2014-03-04
JP2011524853A (ja)	2011-09-08
NZ600238A (en)	2014-04-30
TW201002685A (en)	2010-01-16
MA32483B1 (fr)	2011-07-03
ZA201009073B (en)	2012-03-28
CA2728476C (en)	2017-03-21
GEP20135957B (en)	2013-11-11
TW201240987A (en)	2012-10-16
ECSP11010770A (es)	2011-02-28
ES2676289T3 (es)	2018-07-18
IL209282A0 (en)	2011-01-31
JP5592831B2 (ja)	2014-09-17
US9221836B2 (en)	2015-12-29
PE20140858A1 (es)	2014-08-04
BRPI0914802B1 (pt)	2020-10-27
JP2011157391A (ja)	2011-08-18
AU2009261153B2 (en)	2014-05-22
EA019755B1 (ru)	2014-06-30
CL2010001361A1 (es)	2011-07-29
UY31907A (es)	2010-01-29
SG188117A1 (en)	2013-03-28
CY1120995T1 (el)	2019-12-11
RS57591B1 (sr)	2018-11-30
CA2728476A1 (en)	2009-12-23
HRP20181370T1 (hr)	2018-10-19
SI2297114T1 (sl)	2018-10-30
CO6300862A2 (es)	2011-07-21
JP4800445B2 (ja)	2011-10-26
CN102123990A (zh)	2011-07-13
US20120264733A1 (en)	2012-10-18
US20160046601A1 (en)	2016-02-18
WO2009154300A3 (en)	2010-06-03
DOP2013000123A (es)	2013-11-15
JO3465B1 (ar)	2020-07-05
PL2297114T3 (pl)	2018-10-31
TWI378096B (en)	2012-12-01
EP2297114B1 (en)	2018-06-06
US9045436B2 (en)	2015-06-02
KR20110019428A (ko)	2011-02-25
US20110178057A1 (en)	2011-07-21
CN102123990B (zh)	2014-07-09
DOP2010000381A (es)	2010-12-31
GEP20166443B (en)	2016-03-10
CN103373985B (zh)	2015-10-28
AR072166A1 (es)	2010-08-11
CR20130360A (es)	2013-09-03
US8466282B2 (en)	2013-06-18
WO2009154300A2 (en)	2009-12-23
IL209282A (en)	2015-07-30

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-02-19	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-05-14	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2019-12-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-03-10	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-09-15	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-10-27	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2021-08-24	B25A	Requested transfer of rights approved	Owner name: SCOHIA PHARMA, INC. (JP)
2024-04-09	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 15A ANUIDADE.
2024-07-30	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2779 DE 09-04-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0914802A2 (pt)	2015-08-11	Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo.
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
BRPI1008498A2 (pt)	2015-08-25	Composto, prodroga do composto, medicamento, e, uso de um composto.
BRPI0810646A2 (pt)	2014-11-04	" compostos farmacêuticos ".
BRPI1007018A2 (pt)	2016-03-29	composto, composição farmacêutica, e , uso de um composto.
BRPI0815717A2 (pt)	2015-02-10	Compostos de imidazopirazina.
BRPI1008906A2 (pt)	2016-03-15	composto, composição farmacêutica, e, uso de um composto.
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BRPI0907563A2 (pt)	2015-08-04	Derivados de 4,5-di-hidro-xazol-2-il amina
BRPI0811718A2 (pt)	2014-11-18	Derivados de 3,3-espiroindolinona
CL2007002783S1 (es)	2008-07-04	Inhalador multidosis.
BRPI0815773A2 (pt)	2019-09-24	composto, e, medicamento.
NL2000627A1 (nl)	2007-11-12	Cycloalkylaminoderivaten.
BRPI0813235A2 (pt)	2014-12-23	Combinação anti-helmíntica.
ATE555107T1 (de)	2012-05-15	2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI0716171A2 (pt)	2013-09-17	composto, composiÇço farmacÊutica e uso de um composto.
BRPI0917001A2 (pt)	2016-02-16	composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0816970A2 (pt)	2015-03-24	1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
DE602008005634D1 (de)	2011-04-28	1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
CR10353A (es)	2009-01-09	Nuevos compuestos.
BRPI0814736A2 (pt)	2017-06-06	inalador.
BRPI1009757A2 (pt)	2016-03-15	composto, composição farmacêutica, e , uso de um composto.
ITMI20071002A1 (it)	2008-11-18	Manufatto per edilizia.
BRPI0916363A2 (pt)	2018-05-29	derivados de 4,5-di-hidro-oxazol-2-ila
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.